no category

Phlox Therapeutics raises additional seed funding to develop RNA therapies for genetic laminopathies Funds will advance the company’s lead program into preclinical development 9 May 2023, Naarden, The Netherlands – Phlox Therapeutics (“Phlox”), a private biotechnology company specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead […]

                                                  Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases Research collaboration to target severe form of genetic dilated […]